These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21465637)

  • 1. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients.
    Dupuis LL; Boodhan S; Sung L; Portwine C; Hain R; McCarthy P; Holdsworth M;
    Pediatr Blood Cancer; 2011 Aug; 57(2):191-8. PubMed ID: 21465637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients.
    Dupuis LL; Boodhan S; Holdsworth M; Robinson PD; Hain R; Portwine C; O'Shaughnessy E; Sung L;
    Pediatr Blood Cancer; 2013 Jul; 60(7):1073-82. PubMed ID: 23512831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients.
    Dupuis LL; Robinson PD; Boodhan S; Holdsworth M; Portwine C; Gibson P; Phillips R; Maan C; Stefin N; Sung L;
    Pediatr Blood Cancer; 2014 Aug; 61(8):1506-12. PubMed ID: 24753095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposal for classifying the acute emetogenicity of cancer chemotherapy.
    Hesketh PJ; Kris MG; Grunberg SM; Beck T; Hainsworth JD; Harker G; Aapro MS; Gandara D; Lindley CM
    J Clin Oncol; 1997 Jan; 15(1):103-9. PubMed ID: 8996130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M
    Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
    Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Warr D; Hesketh PJ
    Support Care Cancer; 2017 Jan; 25(1):271-275. PubMed ID: 27501965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors.
    Costa AL; Abreu C; Pacheco TR; Macedo D; Sousa AR; Pulido C; Quintela A; Costa L
    Biomed Res Int; 2015; 2015():309601. PubMed ID: 26421283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
    Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E
    Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline.
    Paw Cho Sing E; Robinson PD; Flank J; Holdsworth M; Thackray J; Freedman J; Gibson P; Orsey AD; Patel P; Phillips R; Portwine C; Raybin JL; Cabral S; Sung L; Dupuis LL
    Pediatr Blood Cancer; 2019 May; 66(5):e27646. PubMed ID: 30729654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
    Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
    BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.
    Grunberg SM; Osoba D; Hesketh PJ; Gralla RJ; Borjeson S; Rapoport BL; du Bois A; Tonato M
    Support Care Cancer; 2005 Feb; 13(2):80-4. PubMed ID: 15599601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
    De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
    Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.
    Dupuis LL; Sung L; Molassiotis A; Orsey AD; Tissing W; van de Wetering M
    Support Care Cancer; 2017 Jan; 25(1):323-331. PubMed ID: 27565788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals.
    McKinnon K; Jupp J; Ghosh S; Digout C; Eason S; Romanick M
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27488. PubMed ID: 30318842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update.
    Patel P; Robinson PD; Thackray J; Flank J; Holdsworth MT; Gibson P; Orsey A; Portwine C; Freedman J; Madden JR; Phillips R; Sung L; Dupuis LL
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28453189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
    Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.